ZVRA
ZEVRA THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$11.17
+8.87%Year over year
Reported trailing growth
- Revenue
- +75.1%
- EBITDA
- +23.8%
- EBIT
- +153.0%
- EPS
- +105.5%
- Free cash flow
- +258.0%
- Operating cash flow
- +265.8%
Forward estimates
Based on analyst estimates
- Revenue
- +16.4%
- EBITDA
- -0.7%
- EPS
- -23.2%
Three-year CAGR
- Revenue
- +118.8%
- EBITDA
- +229.2%
- EBIT
- +95.1%
- Net income
- +178.9%
- EPS
- +161.4%
- Free cash flow
- +96.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026